Boldenone vs Enclomiphene
Moderate Research vs Well Studied
synergistic Mechanism-based · 55% Enclomiphene supports hormonal recovery from suppression caused by Boldenone. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Boldenone Enclomiphene
Weight 286.41 Da (base) 405.96 Da
Half-life ~14 days (undecylenate) ~10 hours
Type 1-dehydrotestosterone steroid (C19H26O2) Trans-isomer of clomifene (selective estrogen receptor modulator)
Key Benefits
Boldenone
01 Lean, quality muscle gains with minimal water retention compared to testosterone
02 Enhanced vascularity through increased red blood cell production and reduced subcutaneous water
03 Significant increase in appetite, supporting caloric surplus during mass-gaining phases
04 Potent stimulation of erythropoiesis, increasing oxygen-carrying capacity and endurance
05 Lower estrogenic activity than testosterone, reducing the need for aromatase inhibitors
06 Lower androgenic side effects (hair loss, acne, prostate stimulation) than testosterone
07 Favorable anabolic-to-androgenic ratio (100:50 compared to testosterone at 100:100)
08 Improved collagen synthesis reported anecdotally, supporting joint and connective tissue health
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Dosing Protocols
Boldenone
200-400 mg/week (moderate) / 1-2x per week (undecylenate)
Lean Bulk - Moderate 200-400 mg/week 1-2x per week (undecylenate)
Performance Enhancement - Standard 400-600 mg/week 2x per week (undecylenate)
Performance Enhancement - High 600-700 mg/week 2x per week (undecylenate)
Boldenone Cypionate Protocol 200-400 mg/week Every 3-4 days
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
Side Effects
Boldenone
Increased hematocrit and red blood cell count (the primary and most clinically significant side effect, more pronounced than with most other AAS)
Increased appetite (significant and dose-dependent, can be a benefit or hindrance depending on goals)
Anxiety and restlessness ('EQ anxiety' is widely reported anecdotally, particularly at higher doses or in anxiety-prone individuals)
Mild acne and oily skin (less than testosterone due to lower androgenic activity)
Suppression of endogenous testosterone production (profoundly suppressive, as with all AAS)
Mild hair thinning in genetically predisposed individuals (less than testosterone but not absent)
Elevated blood pressure secondary to increased blood volume from erythrocytosis
Increased vascularity (cosmetic effect, but indicative of elevated RBC)
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Contraindications
Polycythemia or elevated hematocrit (above 50% at baseline)
Cardiovascular disease, coronary artery disease, or history of thromboembolic events
Hepatic impairment or liver disease
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Pre-existing anxiety disorders (boldenone may significantly exacerbate anxiety symptoms)
Pregnancy or potential for pregnancy (Category X)
Known hypersensitivity to boldenone or any formulation components
Renal impairment (boldenone metabolites are renally cleared)
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Research Evidence
Boldenone Enclomiphene
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest January 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.